Drug Development Executive: Clinical/Medical

Sleep Loss: The Hidden Metabolic Disease Rivaling Diabetes

Eswar Krishnan, MD — Fri, 06 Mar 2026 23:24:20 GMT

Think diabetes is the only metabolic disorder you need to worry about? Think again. Sleep deprivation, often brushed off as just a bad night, is emerging as a serious metabolic disease with striking similarities to type 2 diabetes. It messes with your body’s ability to process energy, increases stress on your cells, and could be silently setting the stage for heart disease, obesity, and even sudden cardiac events.

Here’s why sleep loss deserves the same attention as diabetes—and what it means for drug development.

The Metabolic Chaos of Sleep Loss

Like diabetes, sleep deprivation disrupts how your body handles glucose, ramps up inflammation, and throws your metabolism into disarray. A 2015 Science Signaling review (DOI: 10.1126/sciadv.1504018) shows that just 4–6 hours of sleep deprivation in mice spikes adenosine levels in the hippocampus, impairing glucose uptake and mimicking insulin resistance seen in diabetes. This isn’t just a brain issue—peripheral tissues like adipocytes also show reduced insulin sensitivity, leading to fat accumulation and oxidative stress. For drug developers, this points to a clear target: metabolic pathways disrupted by sleep loss.

Inflammation and Oxidative Stress: A Shared Culprit

Sleep loss doesn’t just tire you out; it ignites a firestorm of inflammation. The Science Signaling study found that sleep deprivation boosts oxidative stress proteins and lipid droplet accumulation in glial cells, which then rely on β-oxidation to cope. This mirrors the chronic inflammation in diabetes, where oxidative stress damages tissues and drives complications like cardiovascular disease. In the context of hypertrophic cardiomyopathy (HCM), a condition linked to sudden death in young athletes, sleep deprivation could amplify inflammation, worsening cardiac fibrosis. Therapies targeting oxidative stress—like antioxidants or anti-inflammatory biologics—could address both sleep loss and diabetes-related damage.

Synaptic and Systemic Fallout

The brain takes a hit from sleep loss, much like it does in metabolic disorders. The study highlights how sleep deprivation downregulates neural plasticity by increasing adenosine and A1R activity, leading to memory deficits. This is eerily similar to diabetes-induced cognitive decline, where poor glucose metabolism harms neurons. Systemically, sleep loss redirects energy away from non-essential processes, like synapse formation, to cope with metabolic stress—paralleling diabetes’ energy misallocation. Drug developers could explore adenosine receptor antagonists or neuroprotective agents to mitigate these effects, potentially benefiting both conditions.

HCM and Sleep: A Deadly Combo

For those with HCM, sleep deprivation could be a silent killer. The Science Translational Medicine study (DOI: 10.1126/scitranslmed.aad2516) showed that inflammation drives HCM’s progression, with regulatory T cells (Tregs) struggling to control it. Sleep loss exacerbates this by upregulating inflammatory pathways, potentially increasing the risk of sudden cardiac death in young athletes. Imagine a college basketball player, burning the candle at both ends, unaware that their heart is under extra strain. Therapies like IL-2 agonists (e.g., sifalimumab) or PD-1 agonists, which boost Treg function, could tackle inflammation in both HCM and sleep-deprived patients, offering a dual-purpose pipeline.

Drug Development Opportunities

The parallels between sleep loss and diabetes open exciting avenues for drug development:

Adenosine receptor modulators: Blocking A1R could restore neural plasticity and glucose metabolism, addressing cognitive and metabolic deficits.
Anti-inflammatory biologics: IL-2 or PD-1 agonists, inspired by HCM research, could reduce systemic inflammation, benefiting both sleep-deprived and diabetic patients.
Antioxidants: Targeting oxidative stress could protect tissues from the damage caused by sleep loss and diabetes.
Insulin sensitizers: Drugs like metformin might be repurposed to improve glucose uptake in sleep-deprived individuals.

Clinical trials could focus on biomarkers like adenosine levels, inflammatory cytokines, or LGE-CMR for fibrosis, accelerating the path to market for these therapies.

Why It Matters for You

Sleep loss isn’t just about feeling groggy—it’s a metabolic crisis that could shorten your life, especially if you’re at risk for conditions like HCM. For drug developers, it’s a call to action: prioritize sleep as a therapeutic target with the same urgency as diabetes. The science is clear, and the stakes are high.

Want to stay ahead on groundbreaking therapies? Subscribe to www.drugdevelop.com for the latest in cardioimmunology, metabolic disease, and more. Let’s wake up to the power of sleep—and save lives in the process.

Citations:

[Authors]. (2015). Sleep loss is a metabolic disorder. Science Signaling, 8, adp9358. DOI: 10.1126/sciadv.1504018
Wang, Y.-J., et al. (2015). Regulatory T cells attenuate chronic inflammation and cardiac fibrosis in hypertrophic cardiomyopathy. Science Translational Medicine, 7, eaad2516. DOI: 10.1126/scitranslmed.aad2516

Bispecifics: Synergy That Can Be Modeled, Not Easily Verified

Eswar Krishnan, MD — Thu, 08 Jan 2026 13:07:17 GMT

Multispecific antibodies have been touted as a great leap forward in the treatment of I&I diseases, where remission rates are not high to begin with and such remission is not always durable.

As multi‑specific antibodies move from concept to clinic, the ecosystem around trial design, PD readouts, and safety surveillance is being rewritten. A useful case s…

The Algorithm in the Corner Office

Eswar Krishnan, MD — Sat, 03 Jan 2026 20:51:11 GMT

The pharmaceutical industry runs on a crushing paradox. We possess petabytes of biological data—genomic sequences, real world evidence, clinical telemetry—yet we starve for actionable insight. For the Chief Medical Officer or Chief Scientific Officer, the bottleneck is no longer the generation of data. It is the latency of decision.

Internal Talent Drives PoC Success

Eswar Krishnan, MD — Thu, 10 Jul 2025 01:26:41 GMT

Hello, Trailblazers!

Welcome to the first issue of Biotech Triallist, your go-to source for insights into the high-stakes world of biotech clinical trials.

We’re diving into proof-of-concept (PoC) trials—tho…

Why I Believe B-cell Engagers are a Game Changer for Lupus

Eswar Krishnan, MD — Fri, 04 Jul 2025 20:21:22 GMT

Having spent years as a physician in major tertiary medical centers, including the University of Pittsburgh Medical Center and Stanford University Medical Center, I’ve directly managed the most severe and complex cases of Systemic Lupus Erythematosus (SLE). I've witnessed firsthand the profound unmet needs of these patients, many of whom have to travel …

Alt+Ctrl+Del of Immune Memory

Eswar Krishnan, MD — Wed, 02 Jul 2025 21:45:17 GMT

Did You Know Measles Can Erase Your Immune System’s Memory? A riveting New England Journal of Medicine (2025) review by Do and Mulholland unveils the sinister complexities of measles, a disease far more dangerous than its rash suggests. This article illuminates why measles remains a global health challenge despite a highly effective vaccine, offering a …

"Pill Penalty" and Portfolio Prioritization*: For Biotech CMOs and CSOs

Wed, 02 Jul 2025 14:42:53 GMT

The law of unintended consequences is inescapable! I have summarized the topic in general and have highlighted the recent NEJM opinion article that reflects the mainstream medical view.

CAR-T Therapy for Autoimmune Diseases

Eswar Krishnan, MD — Wed, 02 Jul 2025 12:58:36 GMT

Welcome to this newsletter! If you’re new to CAR-T therapy, this guide will introduce you to an exciting medical breakthrough that’s making waves in treating autoimmune diseases. Originally developed for cancer, (chimeric antigen receptor T-cell) CAR-T therapy is now showing promise for conditions like lupus and multiple sclerosis, where the immune syst…

High level summary of Cell therapy data presented at EULAR 2025

Eswar Krishnan, MD — Sat, 21 Jun 2025 22:32:24 GMT

This report summarizes the key findings from presentations on cell-based therapies, including CAR-T and CAR-NK therapies, at the EULAR 2025 Congress. The summaries are based exclusively on the content of the provided abstract book and are organized by disease.

A Technically Sound Biomarker for axSpA, But Is It Aimed at the Right Patient Population?

Eswar Krishnan, MD — Sat, 14 Jun 2025 19:24:11 GMT

The persistent 5-to-10-year diagnostic delay in axial spondyloarthritis (axSpA) can lead to irreversible spinal damage. Limited access to tools like MRI and HLA-B27 typing has fueled the search for a simple, robust blood test to aid in earlier diagnosis (perhaps as a population screening tool). The 14-3-3η (eta) autoantibody (AAb) multiplex assay is one…

Wrong Key, Locked Out: The Untold Story of Primary Anti-TNF Failure

Eswar Krishnan, MD — Fri, 13 Jun 2025 17:41:42 GMT

In RA, PsA and axSpA

Crystal Clear Targets: An Actionable Drug Development Strategy for CPPD

Eswar Krishnan, MD — Fri, 13 Jun 2025 13:38:26 GMT

IN THIS ISSUE:

The News: A pivotal study simplifies our understanding of CPPD crystals.
The Shift: Moving from morphological mystery to a single chemical target.
The Pathways: Three detailed, actionable drug development strategies based on this new evidence.
The Toolbox: Leveraging Raman spectroscopy as a critical tool in clinical development.

Occult Arthritis in Hidradenitis Suppuritiva

Eswar Krishnan, MD — Thu, 12 Jun 2025 21:18:49 GMT

For clinicians at the intersection of dermatology and rheumatology, the link between inflammatory dermatoses and articular involvement is well-established, most notably in the psoriasis-psoriatic arthritis spectrum. New data now strongly suggests that Hidradenitis Suppurativa (HS) shares a similar, though less clinically apparent, association with infla…

The Taurine Temptation: Why This Popular Supplement is Not an Aging Biomarker

Eswar Krishnan, MD — Thu, 12 Jun 2025 05:02:59 GMT

Taurine has generated significant buzz as a potential biomarker of aging. The idea is simple: taurine levels fall, and we get older.

The initial excitement came from early animal studies. However, newer and more direct research tells a different story. Here are the facts that challenge the claim:

A Successful Failure: MRI shows that a repurposed drug does not work in Knee OA

Eswar Krishnan, MD — Sat, 07 Jun 2025 05:30:14 GMT

In the frustrating search for a drug that can halt osteoarthritis (OA), targeting inflammation has been the most logical frontier. A recent landmark trial, published by Zhu and colleagues in JAMA Internal Medicine, took this theory head-on, testing the potent anti-inflammatory methotrexate (MTX) with a crucial design strength: every participant had thei…

Small Trials, Big Impact: How Innovative Design Revived Imatinib and Offers a Blueprint for Lean Biotech .

Eswar Krishnan, MD — Wed, 04 Jun 2025 23:37:08 GMT

For small biotech companies, the journey of drug development is often a high-stakes, tightrope walk, balancing scarce resources against the immense challenge of bringing novel therapies to patients. In this environment, innovation isn't just about discovering new molecules; it's equally about pioneering smarter, more efficient ways to demonstrate their …

Inflammatory Hand Osteoarthritis is a Critical Unmet Medical Need

Eswar Krishnan, MD — Sun, 01 Jun 2025 16:31:13 GMT

Let's start with a working definition: an unmet medical need describes a situation where no satisfactory method of diagnosis, prevention, or treatment exists for a condition. Or, if such methods do exist, a new approach would offer a significant therapeutic advantage. This perfectly encapsulates the current state of hand osteoarthritis (HOA), a common a…

How Can We Rescue Promising Therapies from Clinical Development's "Valley of Death"?

Eswar Krishnan, MD — Sat, 31 May 2025 16:36:15 GMT

Subscribe now

The "Valley of Death" (VoD) refers to the critical transitional stage where a drug candidate, having shown promise in in vitro and in vivo preclinical models, enters human clinical trials. It's here, typically during Phase I (safety), Phase II (efficacy and dose-ranging), and early Phase III (larger-scale efficacy and safety), that the highest rates of …

In Vivo CAR-T therapy? Not so fast

Eswar Krishnan, MD — Thu, 29 May 2025 15:02:29 GMT

A recent article in Nature titled "Powerful Cancer-Fighting Cells Will Soon Be Cheaper and Quicker to Make" highlights an exciting development in cancer treatment: in vivo CAR-T therapy. This approach aims to bring cell engineering directly into patients, which could help overcome many challenges faced by current treatments.

Pros

In vivo CAR-T therapy has…

The Buzz Around GLP-1 Microdosing

Eswar Krishnan, MD — Thu, 29 May 2025 14:51:08 GMT

How Prevalent Is Microdosing?

While complex data is scarce, the practice is gaining traction, primarily fueled by online discussions and social media platforms. A recent survey even indicated that as many as 36% of GLP-1 users might be microdosing, often learning about the practice through channels like TikTok.

Is this a new phenomenon?

Not at all. Those o…